{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:56Z","timestamp":1787020916745,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by a necrotizing vasculitis with tissue and peripheral blood eosinophilia affecting small and medium-sized arteries, capillaries, and veins. Venous thromboembolic events are uncommon in EGPA. Moreover, there are only a few reported cases of EGPA complicated by pulmonary embolism or infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 43-year-old woman with eosinophilic granulomatosis with polyangiitis and acute respiratory and heart failure due to bilateral pulmonary artery thrombosis and left femoral vein thrombosis 12\u00a0years after disease onset. She also had cardiac involvement (myocarditis, pericardial effusion, and diastolic dysfunction), gastrointestinal symptoms, and peripheral neuropathy. The condition was refractory to treatment with systemic corticosteroids, intravenous cyclophosphamide, and mepolizumab, but the thrombosis and associated acute cardiac failure, as well as the cardiac and gastrointestinal symptoms and multiple polyneuropathy, improved after a switch to rituximab. However, the heart failure did not improve sufficiently and the patient continued to need inhaled oxygen at 1 L\/min and asthma exacerbations occurred. We then swapped the patient\u2019s mepolizumab treatment for dupilumab. Not only did she have no further asthma attacks after switching to dupilumab, but also her vasculitis symptoms improved. Oxygen therapy was discontinued as the heart failure improved 5\u00a0months after starting the dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This may be the first case report of the successful treatment by rituximab of pulmonary thromboembolism associated with EGPA. In addition, in this patient, treatment with dupilumab was effective not only for the asthma symptoms but also for the symptoms of vasculitis and heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-021-00639-x","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T12:02:49Z","timestamp":1645876969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi"],"prefix":"10.1186","volume":"18","author":[{"given":"Sei","family":"Adachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyako","family":"Oshikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-4569","authenticated-orcid":false,"given":"Naomi","family":"Tsurikisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"639_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094\u2013100.","journal-title":"Arthritis Rheum"},{"key":"639_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564\u20137.","journal-title":"Ann Rheum Dis"},{"key":"639_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/1076029609348647","volume":"16","author":"PRJ Ames","year":"2010","unstructured":"Ames PRJ, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clinical Applied Thrombosis Hemostasis. 2010;16:628\u201336.","journal-title":"Clinical Applied Thrombosis Hemostasis"},{"key":"639_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1398-9995.2004.00691.x","volume":"60","author":"G Garcia","year":"2005","unstructured":"Garcia G, Achouh L, Cobarzan D, Fichet D, Humbert M. Severe venous thromboembolic disease in Churg-Strauss syndrome. Allergy. 2005;60:409\u201310.","journal-title":"Allergy"},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.18176\/jiaci.0566","volume":"30","author":"J Li","year":"2020","unstructured":"Li J, Yan M, Qin J, Ren L, Wen R. Testicular infarction and pulmonary embolism secondary to nonasthmatic eosinophilic granulomatosis with polyangiitis: a case report. J Investig Allergol Clin Immunol. 2020;30:380\u20131.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"639_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2332\/allergolint.R-07-141","volume":"56","author":"S Ozaki","year":"2007","unstructured":"Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87\u201396.","journal-title":"Allergol Int"},{"key":"639_CR7","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","volume":"60","author":"S Moiseev","year":"2021","unstructured":"Moiseev S, Kronbichler A, Makarov E, Bulanov N, Crnogorac M, Direskeneli H, et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology. 2021;60:4654.","journal-title":"Rheumatology"},{"key":"639_CR8","doi-asserted-by":"publisher","first-page":"2004158","DOI":"10.1183\/13993003.04158-2020","volume":"57","author":"A Bettiol","year":"2021","unstructured":"Bettiol A, Sinico RA, Schiavon F, Monti S, Bozzolo EP, Franceschini F, et al. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Eur Respir J. 2021;57:2004158.","journal-title":"Eur Respir J"},{"key":"639_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi C, Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne JP, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586\u201394.","journal-title":"Arthritis Rheum"},{"key":"639_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"key":"639_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/08916930600972016","volume":"39","author":"JC Bystryn","year":"2006","unstructured":"Bystryn JC, Jiao D. IVIGg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39:601\u20137.","journal-title":"Autoimmunity"},{"key":"639_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1196\/annals.1398.009","volume":"1109","author":"UE Nydegger","year":"2007","unstructured":"Nydegger UE. Immune complex pathophysiology. Ann N Y Acad Sci. 2007;1109:66\u201383.","journal-title":"Ann N Y Acad Sci"},{"key":"639_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1055\/s-0036-1579642","volume":"42","author":"E Silvestri","year":"2016","unstructured":"Silvestri E, Scalera A, Emmi G, Squatrito D, Ciucciarelli L, Cenci C, et al. Thrombosis in autoimmune diseases: a role for immunosuppressive treatments? Semin Thromb Hemost. 2016;42:650\u201361.","journal-title":"Semin Thromb Hemost"},{"key":"639_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1358863X15573838","volume":"20","author":"H Tamaki","year":"2015","unstructured":"Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: a narrative review with emphasis on primary systemic vasculitides. Vasc Med. 2015;20:369\u201376.","journal-title":"Vasc Med"},{"key":"639_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1398-9995.2005.00812.x","volume":"60","author":"V Cottin","year":"2005","unstructured":"Cottin V. Eosinophilic pneumonias. Allergy. 2005;60:841\u201357.","journal-title":"Allergy"},{"key":"639_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","volume":"78","author":"L Guillevin","year":"1999","unstructured":"Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26\u201337.","journal-title":"Medicine (Baltimore)"},{"key":"639_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/cea.13209","volume":"48","author":"N Tsurikisawa","year":"2018","unstructured":"Tsurikisawa N, Oshikata C, Watanabe M, Tsuburai T, Kaneko T, Saito H. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Exp Allergy. 2018;48:1305\u201316.","journal-title":"Clin Exp Allergy"},{"key":"639_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaip.2020.07.038","volume":"9","author":"HC Chang","year":"2021","unstructured":"Chang HC, Chou PC, Lai CY, Tsai HH. Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021;9:445\u201352.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1038\/s41598-021-85852-9","volume":"11","author":"V R\u00e9au","year":"2021","unstructured":"R\u00e9au V, Vall\u00e9e A, Terrier B, Plessier A, Abisror N, Ackermann F, et al. Venous thrombosis and predictors of relapse in eosinophil-related diseases. Sci Rep. 2021;11:6388.","journal-title":"Sci Rep"},{"key":"639_CR20","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","volume":"20","author":"M Akiyama","year":"2021","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review. Autoimmun Rev. 2021;20:102737.","journal-title":"Autoimmun Rev"},{"key":"639_CR21","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5:e000905.","journal-title":"RMD Open"},{"key":"639_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semarthrit.2015.03.004","volume":"45","author":"A Fanouriakids","year":"2015","unstructured":"Fanouriakids A, Kougkas N, Vassilopoulos D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: case report and review of current clinical evidence. Semin Arthritis Rheum. 2015;45:60\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"639_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","volume":"33","author":"N Tsurikisawa","year":"2013","unstructured":"Tsurikisawa N, Saito H, Oshikata C, et al. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol. 2013;33:965\u201376.","journal-title":"J Clin Immunol"},{"key":"639_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cea.13514","volume":"50","author":"G Patel","year":"2020","unstructured":"Patel G, Pan J, Ye L, Shen X, Rosloff D, D\u2019Souza SS, et al. Blockade of IL-4R\u03b1 inhibits group 2 innate lymphoid cell responses in asthma patients. Clin Exp Allergy. 2020;50:267\u201370.","journal-title":"Clin Exp Allergy"},{"key":"639_CR25","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1016\/j.jaip.2020.06.052","volume":"8","author":"J Galant-Swafford","year":"2020","unstructured":"Galant-Swafford J, Geng B, Leibel S, Akuthota P, Tucker S, Cernec-Kohan M, et al. Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab. J Allergy Clin Immunol Pract. 2020;8:3463\u2013646.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"639_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cea.13614","volume":"50","author":"C Dupin","year":"2020","unstructured":"Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, Blay FD, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50:789\u201398.","journal-title":"Clin Exp Allergy"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00639-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00639-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00639-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T12:02:51Z","timestamp":1645876971000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00639-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00639-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-895751\/v1","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"11 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The hospital ethics committee approved the study in accordance with the Helsinki Declaration. The ethics committee at our hospital approved the study, and written informed consent was obtained from all patients or their legal representatives. The ethics approval number at Hiratsuka City Hospital was 30-013.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient. We obtained the patient\u2019s written informed consent to publish details of her case","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No author has any conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}